Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2201073119
Abstract: Significance Breast cancers that overexpress oncogenic tyrosine kinase receptor HER2 are treated with HER2-targeting antibodies (such as trastuzumab) or small-molecule kinase inhibitors (such as lapatinib). However, most patients with metastatic HER2+ breast cancer have intrinsic… read more here.
Keywords: kinase; her2 targeting; cdk8; resistance ... See more keywords
Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2021.1982698
Abstract: ABSTRACT Introduction Although various new drugs have been developed, the prognosis of therapeutic advances for metastatic gastric cancer is insufficient. Trastuzumab deruxtecan (T-DXd), a new human epidermal growth factor receptor 2 (HER2)-targeting antibody–drug conjugate (ADC),… read more here.
Keywords: gastric cancer; her2 targeting; trastuzumab deruxtecan; cancer ... See more keywords
Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-b179
Abstract: Background: HER2 is a well-established therapeutic target in breast and gastric cancer. Although HER2-targeting therapies are available for HER2-overexpressed breast and gastric cancer, the combination with chemotherapy is still necessary. Recent preclinical and clinical studies… read more here.
Keywords: combination; single agent; her2 targeting; tas0728 ... See more keywords
Abstract 2702: GQ1001 is a next generation HER2-targeting ADC with excellent druggability, safety and potency
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2702
Abstract: Background: GQ1001 was developed to overcome the current limitation of existing HER2 ADCs by using the next generation site-specific conjugation and a stable linker technology, coined the intelligent ligase-dependent conjugation (iLDC) technology. iLDC provides a… read more here.
Keywords: gq1001; her2; her2 targeting; generation ... See more keywords
DS-8201a, a HER2-targeting antibody-drug conjugate, to elicit immune responses and benefits in combination with an anti-PD-1 antibody.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.1031
Abstract: 1031Background: DS-8201a, a HER2-targeting antibody–drug conjugate (ADC), with a topoisomerase I inhibitor, exatecan drivative (DX-8951 derivative, DXd) has been shown to have antitumor effects in preclinical xenograft models and clinical trials, but the involvement of… read more here.
Keywords: her2 targeting; drug conjugate; targeting antibody; 8201a her2 ... See more keywords